Individualization of drug therapy: an historical perspective

Arthur J. Atkinson

doi:10.12793/tcp.2014.22.2.52

Journal List > Transl Clin Pharmacol > v.22(2) > 1082593

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Atkinson: Individualization of drug therapy: an historical perspective

Original Article

Translational and Clinical Pharmacology 2014;22(2):52-54.

Published online: 30 December 2014

DOI: https://doi.org/10.12793/tcp.2014.22.2.52

Individualization of drug therapy: an historical perspective

Arthur J. Atkinson, Jr.^∗

Department of Pharmacology Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

^∗Correspondence: A. J. Atkinson, Jr.; E-mail: art_atkinson@msn.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Although therapeutic drug monitoring, pharmacokinetics, and pharmacogenetics/ pharmacogenomics are conventionally considered in isolation, when applied to patient care, they are really three chapters in a continuing story that has as its theme the optimization of pharmacotherapy. This has been variously referred to as "rational drug therapy", "individualization of drug therapy", and "personalized medi-cine". However, the goal of improved drug therapy has been the same.

References

1. Wuth O. Rational bromide treatment: New methods for its control. JAMA. 1927; 88:2013–2017.

2. Shannon JA. Chemotherapy in malaria. Bull NY Acad Sci. 1947; 22:345–357.

3. Brodie BB, Udenfriend S. The estimation of quinine in human plasma with a note on the estimation of quinidine. J Pharmacol Exp Ther. 1943; 76:154–158.

4. Brodie BB, Udenfriend S. The estimation of atabrine in biological fluids and tissues. J Biol Chem. 1943; 151:299–317.

5. Mark LG, Kayden HJ, Steele JM, Cooper R, Berlin I, Rovenstine EA, et al. The physiological disposition and cardiac effects of procaine amide. J Pharmacol Exp Ther. 1951; 102:5–15.

6. Atkinson AJ Jr, Ambre JJ. Kalman and Clark's Drug Assay: The Strategy of Therapeutic Drug Monitoring. 2nd ed.Masson, New York;1984.

7. Jolley ME, Stroupe SD, Schwenzer KS, Wang CJ, Lu-Steffes M, Hill HD, et al. Fluorescence polarization immunoassay. III. An automated system for therapeutic drug determination. Clin Chem. 1981; 27:1575–1579.

8. Juel R. The 1978 College of American Pathologists therapeutic monitoring interlaboratory survey program. Am J Clin Pathol. 1979; 72(2 Suppl):): 306–319.

9. Paalzow LK. Torsten Teorell, the father of pharmacokinetics. Ups J Med Sci. 1995; 100:41–46.

10. Gaddum JH. Repeated doses of drugs. Nature. 1944; 153:144.

11. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med. 1974; 57:63–68.

12. Dettli L. Individualization of drug dosage i patients with renal disease. Med Clin North Am. 1974; 58:977–985.

13. CDER CBER. Pharmacokinetics in patients with impaired renal function – study design, data analysis, and impact on dosing and labeling. Draft Guidance for Industry. Rockville: FDA;(Internet at. http://www.fda/gov/down-loads/Drugs/GuidanceComplianceRegulato-ryInformation/Guidances/UCM204959.pdf. ); March. 2010.

14. Sjöqvist F. A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry. 1971; 6:147–169.

15. Alving AS, Carson PE, Flannagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956; 124:484–485.

16. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960; 2:485–491.

17. Eichelbaum M, Spannbrucker N, Dengler HJ. N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedeberg's Arch Pharmacol. 1975; 287:(. (Suppl):): R94.

18. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012; 27:55–67.

19. Zineh I, Pacanowski MA. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration. Pharmacotherapy. 2011; 31:729–735. doi: 10.1592/phco.31.8.729.

20. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011; 89:464–467. doi: 10.1038/clpt.2010.279.

21. Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014; 95:423–431. doi: 10.1038/clpt.2013.229.

22. Sjöqvist F. The past, present and future of clinical pharmacology. Eur J Clin Pharmacol. 1999; 55:553–557.

23. Atkinson AJ Jr, Reidenberg MM, Thompson WL, Clinical Pharmacology. In: Greenberger N, Ed. MKSAP VI Syllabus, Philadelphia, Am Col Phys. 1982. 85–96.

24. Levy KD, Decker BS, Carpenter JS, Flockhart DA, Dexter PR, Desta Z, et al. Prerequisites to implementing a pharmacogenomics program in a large healthcare system. Clin Pharmacol Ther. 2014; 96:307–309. doi: 10.1038/clpt.2014. 101.

Figure 1.

Drug prescribing flow chart showing the potential application of pharmacogenetics/pharmacogenomics (PGX), pharmacokinetics (PK), and therapeutic drug monitoring (TDM) at each step of the prescribing process.

TOOLS

Similar articles